Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacoeconomic advantages of subcutaneous versus intravenous immunoglobulin treatment in a Canadian pediatric center.

× No keyword cloud information.

16 in total

1. SCIg vs. IVIg: let's give patients the choice!

Authors: K Samaan; M C Levasseur; H Decaluwe; C St-Cyr; H Chapdelaine; A Des Roches; E Haddad
Journal: J Clin Immunol Date: 2014-06-03 Impact factor: 8.317

2. Primary immunodeficiency disease: a cost-utility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia.

Authors: Tanja M Windegger; Son Nghiem; Kim-Huong Nguyen; Yoke L Fung; Paul A Scuffham
Journal: Blood Transfus Date: 2019-08-05 Impact factor: 3.443

Review 3. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease.

Authors: S Jolles; J S Orange; A Gardulf; M R Stein; R Shapiro; M Borte; M Berger
Journal: Clin Exp Immunol Date: 2015-02 Impact factor: 4.330

Review 4. A Canadian perspective on the use of immunoglobulin therapy to reduce infectious complications in chronic lymphocytic leukemia.

Authors: S Lachance; A L Christofides; J K Lee; L H Sehn; B C Ritchie; C Shustik; D A Stewart; C L Toze; E Haddad; D C Vinh
Journal: Curr Oncol Date: 2016-02-18 Impact factor: 3.677

Review 5. Advances in basic and clinical immunology in 2013.

Authors: Javier Chinen; Luigi D Notarangelo; William T Shearer
Journal: J Allergy Clin Immunol Date: 2014-02-28 Impact factor: 10.793

Review 6. Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin?

Authors: Fatima Dhalla; Mary Lucas; Anna Schuh; Malini Bhole; Rashmi Jain; Smita Y Patel; Siraj Misbah; Helen Chapel
Journal: J Clin Immunol Date: 2014-02-21 Impact factor: 8.317

7. Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations.

Authors: M Ponsford; E Carne; C Kingdon; C Joyce; C Price; C Williams; T El-Shanawany; P Williams; S Jolles
Journal: Clin Exp Immunol Date: 2015-09-22 Impact factor: 4.330

8. Switching Patients to Home-Based Subcutaneous Immunoglobulin: an Economic Evaluation of an Interprofessional Drug Therapy Management Program.

Authors: Clemence Perraudin; Aline Bourdin; Francois Spertini; Jérôme Berger; Olivier Bugnon
Journal: J Clin Immunol Date: 2016-05-02 Impact factor: 8.317

Review 9. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review.

Authors: Jenny Lingman-Framme; Anders Fasth
Journal: Drugs Date: 2013-08 Impact factor: 9.546

10. Home-Based Subcutaneous Infusion of Immunoglobulin for Primary and Secondary Immunodeficiencies: A Health Technology Assessment.

Authors:
Journal: Ont Health Technol Assess Ser Date: 2017-11-01